Abstract:Previous studies have demonstrated that pioglitazone (Piog), a peroxisome proliferator-activated receptor gamma (PPARγ) agonist, inhibits ischemia-induced brain injury. Piog has also been shown to exert anti-inflammatory effects by attenuation of nuclear factor-κB (NF-κB) activation after myocardial ischemia/reperfusion injury. Because NF-κB is known to play a major role in the pathophysiology of brain ischemia, the present study was undertaken to elucidate whether pioglitazone attenuates ischemic neuronal damage through PPARγ-mediated suppression of NF-κB apoptotic signaling pathway. Permanent middle cerebral artery occlusion (pMCAO) model was induced by using an intraluminal filament technique in rats. Piog was administrated i.p. twice (24 h before and at the time of ischemia insult) or once (10 min after ischemia). The neuroprotection of Piog was analyzed by assessing neurological deficits, infarction volume and morphological changes. The inhibition of NF-κB signaling pathway by Piog was evaluated by detecting the nuclear translocation of NF-κB p65 with immunohistochemistry and its target gene p53 by real-time PCR, and the expression of phospholated NF-κB p65 (p- NF-κB p65) in primary cultured neurons and the protein levels of IκBα and p-ERK in the ischemic cortex or striatum with Western blotting analysis. The contribution of a PPARγ mechanism to Piog's inhibitory effects on NF-κB and neuroprotection was evaluated by pretreatment with the PPARγ irreversible antagonist GW9662. In vitro ischemia in cultured primary neurons was induced by the oxygen-glucose deprivation (OGD) and the protective effect of Piog on cultured neurons was measured by lactate dehydrogenase (LDH) assay. Piog (0.5, 1, 2 mg/kg) reduced infarction volume, and improved morphological changes and motor deficits. Piog markedly up-regulated the protein levels of IκBα or p-ERK 6 h or 12 h after ischemia. Piog reduced the nuclear translocation of NF-κB p65 in the ischemic cortical cells and repressed the expression of p53 12 h after ischemia. Pre-treatment with GW9662 blocked Piog-elicited reduction in infarction volume, the increase in protein levels of IκBα and p-ERK, the reduction in the nuclear translocation of NF-κB subunit p65 and the repression of p53 mRNA expression. In addition, Piog attenuated the OGD-induced neuronal damage and inhibited the OGD-induced increases in p- NF-κB p65 in neurons. The present findings suggest that Piog's neuroprotection appears to be associated with PPARγ-mediated suppression of NF-κB signaling pathway.

Pioglitazone Protects Tubular Cells Against Hypoxia/reoxygenation Injury Through Enhancing Autophagy Via AMPK-mTOR Signaling Pathway

Pioglitazone Protects Against Renal Ischemia-Reperfusion Injury via the AMP-Activated Protein Kinase-Regulated Autophagy Pathway

Pioglitazone Attenuates Reoxygenation Injury in Renal Tubular NRK-52E Cells Exposed to High Glucose Via Inhibiting Oxidative Stress and Endoplasmic Reticulum Stress

Pioglitazone protects against renal ischemia-reperfusion injury by enhancing antioxidant capacity.

Protective effects of pioglitazone on renal ischemia-reperfusion injury in mice.

Pioglitazone Improves Mitochondrial Function in the Remnant Kidney and Protects Against Renal Fibrosis in 5/6 Nephrectomized Rats.

Pioglitazone ameliorates ischemia/reperfusion-induced acute kidney injury via oxidative stress attenuation and NLRP3 inflammasome

Pioglitazone Confers Neuroprotection Against Ischemia-Induced Pyroptosis due to its Inhibitory Effects on HMGB-1/RAGE and Rac1/ROS Pathway by Activating PPAR-ɤ.

Pioglitazone, a Peroxisome Proliferator-Activated Receptor Γ Agonist, Ameliorates Chronic Kidney Disease by Enhancing Antioxidative Capacity and Attenuating Angiogenesis in the Kidney of a 5/6 Nephrectomized Rat Model

Pioglitazone Attenuates Advanced Glycation End Products-Induced Apoptosis and Calcification by Modulating Autophagy in Tendon-Derived Stem Cells

Pioglitazone Protected Against Cardiac Hypertrophy Via Inhibiting AKT/GSK3β and MAPK Signaling Pathways.

Protective Effect of Pioglitazone on Retinal Ischemia/Reperfusion Injury in Rats

Protective effects of pioglitazone in renal ischemia–reperfusion injury (RIRI): focus on oxidative stress and inflammation

Neuroprotective Effects of Pioglitazone in a Rat Model of Permanent Focal Cerebral Ischemia Are Associated with Peroxisome Proliferator-Activated Receptor Gamma-Mediated Suppression of Nuclear Factor-Κb Signaling Pathway

Pioglitazone Protects PC12 Cells Against Oxidative Stress Injury: an in Vitro Study of Its Antiapoptotic Effects Via the PPARγ Pathway.

Pioglitazone Alleviates Cisplatin Nephrotoxicity by Suppressing Mitochondria‐mediated Apoptosis Via SIRT1/p53 Signalling

Pioglitazone Ameliorates Retinal Ischemia/Reperfusion Injury Via Suppressing Nlrp3 Inflammasome Activities

Pioglitazone Protect PC12 Cells Against Oxidative Stress Injury: Involvement of Anti-apoptotic Effect and PPARγ Activation

Protective Effect of Pioglitazone on Kidney Injury in Diabetic Rats.

Protective effects of preischemic treatment with pioglitazone, a peroxisome proliferator-activated receptor-gamma ligand, on lung ischemia-reperfusion injury in rats

Protective effects of pioglitazone on vascular endothelial cell dysfunction induced by high glucose via inhibition of IKKα/β-NFκB signaling mediated by PPARγ in vitro.